The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study: Docetaxel-cisplatin and pro drug tegafur (TPF) as neoadjuvant treatment  in advanced patients with head and neck cancer (HNC): Results and correlation between tandem magnesium/creatinine and toxicity.
Manuel Santos Ortega
No relevant relationships to disclose
Gaspar Esquerdo
No relevant relationships to disclose
Jose Manuel Cervera Grau
No relevant relationships to disclose
Enrique Barrajon
No relevant relationships to disclose
Silvia Rodriguez Villalva
No relevant relationships to disclose
Marina De Piaggio
No relevant relationships to disclose
Rafael Peiro
No relevant relationships to disclose
Rita De Sanctis
No relevant relationships to disclose
Macarena Paz Espinoza Venegas
No relevant relationships to disclose